MLH1 deletion
|
Endometrial Cancer
|
MLH1 deletion
|
Endometrial Cancer
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
MLH1 deletion
|
Prostate Cancer
|
MLH1 deletion
|
Prostate Cancer
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
MLH1 deletion
|
Colon Cancer
|
MLH1 deletion
|
Colon Cancer
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|